CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Hydroxychloroquine plus NitazoxanideWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug554 Chest MRI Wiki 1.00
drug2314 Standard care Wiki 0.38

Correlated MeSH Terms (5)


Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D011014 Pneumonia NIH 0.06
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials


1 Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope

In December 2019, a new infectious respiratory disease emerged in Wuhan, Hubei province, China. An initial cluster of infections was linked to Huanan seafood market, potentially due to animal contact. Subsequently, human-to-human transmission occurred and the disease, now termed coronavirus disease 19 (COVID-19) rapidly spread within China and all over the world. A novel coronavirus, SARS-coronavirus 2 (SARS-CoV-2), which is closely related to SARS-CoV, was detected in patients and is believed to be the etiologic agent of the new lung disease. The causative agent of the current COVID-19 pandemic, SARS-CoV-2, is a single stranded positive sense RNA virus that is closely related to severe acute respiratory syndrome coronavirus (SARS-CoV).

NCT04361318 COVID-19 Combination Product: Hydroxychloroquine plus Nitazoxanide Other: Standard care

Primary Outcomes

Description: PCR analysis of COVID-19 RNA in patients

Measure: Number of patients with COVID-19-negative PCR

Time: within 10 days to become PCR negative

Secondary Outcomes

Description: improved breaths per minute for the patients

Measure: Number of patients with improved respiratory rate

Time: within 30 days

Description: Change in PaO2 in mmHg of the patients

Measure: Number of patients with improved PaO2

Time: within 30 days

Description: Serum IL6 in pg/mL of the patients

Measure: Number of patients with normalized Serum IL6

Time: within 30 days

Description: Serum TNFα in pg/mL of the patients

Measure: Number of patients with normalized Serum TNFα

Time: within 30 days

Description: Serum iron in microgram/dL of the patients

Measure: Number of patients with normalized Serum iron

Time: within 30 days

Description: Serum ferritinin microgram/L of the patients

Measure: Number of patients with normalized Serum ferritin

Time: within 30 days

Description: International normalized ratio "INR" for prothrombin time of 2

Measure: Number of patients with normalized International normalized ratio "INR" for prothrombin time

Time: within 30 days

Description: CBC for lymphocyte count in cells/microliter

Measure: Number of patients with normalized complete blood count "CBC"

Time: within 30 days

Description: Mortality rate [number of dead patients/total number of treated patients]

Measure: The Mortality rate among treated patients

Time: within 30 days


No related HPO nodes (Using clinical trials)